The WuXi AppTec Research Service Division (RSD) supports clients in the discovery and development of future therapeutics. Through comprehensive discovery and technology platforms, peer-recognized scientific leadership and expertise in oncology, immunology, infectious disease, neurosciences, fibrosis, cardiovascular and metabolic disease, RSD works collaboratively to rapidly advance programs from target through to preclinical selection and beyond.
RSD’s discovery platform encompasses biology, chemistry, structural biology, biophysics and ADME/PK, in addition to the capabilities of newly acquired HD Biosciences (HDB), and is trusted by over 3,000 international clients, ranging from pharma and biotech to academia and non-profit institutions.
This integration of capabilities allows a collaborative environment, enabling enhanced efficiency and productivity. WuXi AppTec RSD strives to continually develop and enhance its scientific capabilities and technology to maintain its industry leading position. We aim to provide outstanding services to our existing partners and to the broader discovery community!